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ABSTRACT
This study assessed the risk of haematological, renal and hepatic toxicity associated with amphotericin B
lipid complex (ABLC; Abelcet) in a multicentre, open-label, non-comparative study of 93 patients from
17 different hospitals who received ABLC because of proven or suspected systemic fungal infection or
leishmaniasis. Most (66%) patients had onco-haematological diseases. Optimum treatment with ABLC
comprised a slow (2-h) infusion dose of 5 mg ⁄kg ⁄day for a minimum period of 14 days. Biochemical
and haematological parameters were measured pre-, during and post-treatment. In the overall patient
group, the mean serum creatinine concentration was similar pre- and post-study (1.00 ± 1.14 mg ⁄dL vs.
1.20 ± 1.19 mg ⁄dL; p > 0.05). There were no significant changes pre- and post-treatment in concentra-
tions of haemoglobin, potassium, transaminases and bilirubin. There was no significant correlation
between the dose administered and the concentrations of serum creatinine (Spearmann 0.22). There was
no greater nephrotoxicity in the patients with previous renal failure, or in those who had received
amphotericin B previously. There were serious adverse events in five patients, but other alternative
causes that could explain these events were present in three of these patients. Fevers or chills were
experienced by 23% of the patients during the ABLC infusion, but only in one case did this necessitate
the suspension of treatment. It was concluded that ABLC is a drug with low nephrotoxicity, even when
administered to patients with pre-existing renal insufficiency. Adverse events were generally slight or
moderate, and were managed easily with appropriate pre-medication.
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INTRODUCTION
There has been an increase in the incidence of
nosocomial fungal infections, associated with the
increase in the number of severely immunocom-
promised patients, such as those receiving ther-
apy for onco-haematological illnesses and those
receiving transplants of bone marrow and other
organs. Furthermore, there are increasing num-
bers of cases of fungal infections in post-operative
patients, patients with chronic bronchitis under-
going steroid treatment and patients with AIDS
[1–7]. The preferred drug for empirical
anti-mycosis treatment in immunocompromised
patients is usually conventional amphotericin B
[8–11], but unfortunately many patients experi-
ence significant renal and haematological toxicity
when treated with this agent [12–14].
Several clinical studies have demonstrated the
potential advantages of lipid-based formulations
of amphotericin B. Of these, amphotericin B lipid
complex (ABLC) is currently considered to be an
efficacious and better-tolerated alternative for the
treatment of systemic fungal infections [15,16]. Its
efficacy has been demonstrated against severe
and potentially lethal systemic mycoses in
patients who have relapsed following other
anti-mycosis treatment and ⁄ or with significant
deterioration in renal function [17–20]. Such
patients include those with severe neutropenia
or haematological neoplasia, those undergoing
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bone marrow transplants, and patients with
AIDS.
ABLC appears to preserve, and on some occa-
sions to improve, the renal function of patients
with antecedents of renal insufficiency before the
treatment, and, in some patients with nephrotox-
icity induced by conventional amphotericin B, the
treatment with ABLC conserves, or even
improves, deteriorating renal function [21–24].
The commonest adverse clinical reactions, such as
chills, fever, nausea and vomiting, are related to
the administration of amphotericin B alone and
usually appear during the first few days of
treatment. Adverse events related to the admin-
istration of ABLC appear to be generally light or
moderate, and appear only during the first 2 days
of treatment. The prevalence and the gravity of
the adverse events associated with ABLC treat-
ment appear to be substantially less than those
observed with conventional amphotericin B
[25–27]. Therefore, the aim of the present study
was to conduct a pharmacovigilance assessment
of possible adverse reactions and their incidence
in patients treated with ABLC [27,28].
PATIENTS AND METHODS
Design and description of the study
The study, initiated in June 1996 and concluded in December
1998, was an open-label, non-comparative and prospective
study that included patients with proven or suspected severe
systemic fungal infection or leishmaniasis who were treated
with ABLC (Abelcet; The Liposome Company, London, UK).
The patients were recruited from 17 Spanish hospitals and
were included for one of the following clinical reasons: adverse
reaction to a previous systemic antifungal agent; development
of toxicity associated with conventional amphotericin B treat-
ment, defined as (1) nephrotoxicity (serum creatinine
> 2.0 mg ⁄dL in adults and > 1.5 mg ⁄dL in children) or (2)
acute severe toxicity; pre-existing renal insufficiency from
other causes; or use of ABLC as the drug-of-choice. Exclusion
criteria were pregnancy, lactation or previous hypersensitivity
to amphotericin B.
The recommended dose of ABLC was 5 mg ⁄kg ⁄day,
although the responsible physician retained the right to
modify this according to the patient’s clinical condition. The
recommended duration of treatment was for at least 14 days.
In the case of nephrotoxicity or a non-serious adverse event, a
daily dose reduction of 1 mg ⁄ kg over 3 days was recommen-
ded. The responsible physician retained the right to suspend
treatment at any time if required by the patient’s clinical
condition.
All the patients were evaluated at the start of the study
(baseline evaluation). Demographic data were recorded, as
were vital signs, reason for inclusion, primary underlying
clinical condition, results of physical examination and meas-
urements of haemoglobin, haematocrit, leukocyte count, plate-
lets, serum creatinine, serum potassium, total bilirubin and the
transaminases. Patients were assessed daily, with special
attention to possible adverse reactions. Laboratory analyses
were performed weekly and included the measurements listed
above.
Fungal infection was defined as: ‘definite’ when its presence
was confirmed by culture, histology, positive antigen titres for
Cryptococcus in serum and ⁄or positive ligase chain reaction;
‘probable’ if there was no histological evidence or culture; and
‘suspected’ if the only evidence comprised clinical symptoms,
suggestive X-rays, an absence of response to antibacterial
treatment, or culture only from lung secretions.
Treatment with ABLC could be interrupted for any of the
following reasons: conclusion of the study; progression of the
fungal infection; development of severe toxicity or another
serious adverse event; reassessment of the patient indicating
absence of fungal infection; or a decision of the patient or the
attending physician in the best interests of the patient.
Definitions of adverse events
An adverse event was defined as a change associated with the
drug under investigation that was prejudicial to the structure
(indicated by signs) or function (indicated by symptoms) of the
patient. By convention, a ‘serious’ adverse event is lethal or
potentially life-threatening, produces a severe or permanent
incapacity, a cancer or a congenital anomaly that requires, or
prolongs, hospitalisation, or is associated with an overdose of
the agent under investigation. An unexpected adverse event is
one whose natural history, gravity or frequency has not been
identified previously. Renal insufficiency was defined as a
serum creatinine level > 2 mg ⁄dL, or an increase in serum
creatinine of at least 50% with respect to the basal level,
and ⁄or when creatinine clearance was < 50 mL ⁄min. Hypoka-
laemia was defined as a serum potassium level < 3.5 mEq ⁄mL.
The gravity of an adverse clinical event was classified
according to the criteria of the World Health Organization as:
‘slight’ when the adverse event was transient and tolerable, in
which case no special treatment was necessary; ‘moderate’
when the adverse event induced discomfort and interfered
with the usual habits and activities of the patient, in which case
treatment of symptoms was possible; and ‘severe’ when the
adverse event interfered considerably with the usual activities
of the patient and was incapacitating or potentially life-
threatening, and hospitalisation and specific treatment was
necessary.
An adverse clinical event was considered to be: ‘unrelated’
when tests indicated that the adverse reaction had an aetiology
unrelated to the drug; ‘possibly related’ when the adverse
reaction was related in a temporal sequence to administration
of the drug, but, nevertheless, could have an alternative
aetiology that might explain the adverse event; or ‘related’
when the adverse event ceased when administration of the
drug was interrupted, there appeared to be no other potential
aetiology, and the reaction reappeared on re-administration of
the drug.
Statistical analysis
Statistical analyses were performed by a specialist external
centre (Centro de Investigacio´n Bioestadı´stica, Cibest, Madrid).
SAS (SAS Inc., Cary, NC, USA) software was used to construct
the database and to perform parts of the descriptive statistics.
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Absolute frequencies and percentages were used in the PROC
TABULATE of SAS ⁄BASE procedure to describe categorical
variables; for continuous variables, the PROC UNIVARIATE
and PROC TABULATE procedures were used. Comparison of
variables was done with the McNemar test, the signed-rank
test and the correlation tests of Pearson and Spearmann.
RESULTS
Principal characteristics of the patients
There were 93 patients in the study with a mean
age of 43 ± 21.8 years (range 1–81 years), of
whom 60 (64%) were males. The mean dose
administered was 235 ± 116 mg ⁄day (range
9–500 mg ⁄day) and the total accumulated dose
was 2894 ± 2230 mg (30–10 200 mg). Clinical
indications for inclusion in the study are listed
in Table 1. The underlying clinical pathology of
the patients is summarised in Table 2. Three
patients had visceral leishmaniasis, while the
remainder were diagnosed with different forms
of systemic mycosis (Table 3). The diagnosis of
mycosis was suspected in 42 (47%), probable in
21 (23%), and definite in 27 (30%) cases.
Assessment of renal toxicity
As shown in Fig. 1, there were no significant
changes in the median serum creatinine concen-
trations in the overall patient group over the long
term. The percentage of patients with serum
creatinine concentrations > 2 mg ⁄dL at the start
of the treatment did not differ significantly from
the percentage of patients with creatinine
> 2 mg ⁄dL at the end of the treatment (18 ⁄ 81 vs.
25 ⁄ 81, respectively; McNemar test, p 0.127). For
those patients with serum creatinine levels
> 2 mg ⁄dL at the start of the study, a significant
decrease in the creatinine concentration was
observed at the end of the treatment period
(Fig. 2).
In the 19 patients for whom ABLC was pre-
scribed because of renal insufficiency (creatinine
> 2 mg ⁄dL) unrelated to the previous use of
amphotericin B, a median decrease in the serum
creatinine concentration was observed from
2.8 ± 1.55 mg ⁄dL (range 1–6.4 mg ⁄dL) to 2.5 ±
1.41 mg ⁄dL (range 0.8–7 mg ⁄dL), although this
was not statistically significant (sign test,
p 0.43). An improvement in renal function was
observed in seven of these 19 patients at the end
of treatment with ABLC. Similarly, a non-signifi-
cant decrease (from 1.70 ± 0.66 mg ⁄dL, range
0.40–2.90 mg ⁄dL, to 1.20 ± 0.78 mg ⁄dL, range
Table 1. Clinical indications for inclusion of patients
(n = 93) in the study
Clinical indication na %
First-choice antifungal agent 44 42
Toxicityb with conventional amphotericin B 21 20
Relapse with other antifungal agents 21 20
Previous renal insufficiency 19 18
aEleven patients had more than one reason for being included in the study.
bNephrotoxicity (12 cases) or intolerance (nine cases).
Table 2. Primary underlying clinical pathology in patients
included in the study
Underlying pathology n %
Onco-haematological disease 56 60
Critical illness; admittance to intensive care 19 21
AIDS 6 7
Organ transplant 4 4
Systemic fungal infection 1 1
COPD 2 2
Premature birth 1 2
Visceral leishmaniasis 3 3
Others 1 1
COPD, chronic obstructive pulmonary disease.
Table 3. ‘Demonstrated’ and ‘probable’ forms of systemic
mycosis among the patients in the study
Mycosis type n %
Disseminated candidiasis 13 27
Candidaemia 9 19
Visceral candidiasis 9 19
Mucocutaneous and oesophageal candidiasis 2 4
Hepatosplenic candidiasis 1 2
Endocarditis caused by Candida spp. 1 2
Pulmonary aspergillosis 7 15
Disseminated aspergillosis 2 4
Disseminated cryptococcosis 1 2
Disseminated fusariosis 1 2
Others 2 4
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Fig. 1. Median serum creatinine concentration change
following treatment with amphotericin B lipid complex
in the overall study population.
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0.60–3.20 mg ⁄dL, sign test p 0.13) was observed
for 13 patients for whom baseline data were
available and who were included because of
toxicity resulting from previous amphotericin B
therapy.
There was no significant correlation between
the mean dose of ABLC administered and the
final serum creatinine concentrations (Spearman
range correlation test 0.22), or between the accu-
mulated dose of ABLC and the concentrations of
creatinine at the end of treatment (correlation
r 0.22).
Assessment of other toxic effects
There was no statistically significant difference
between serum potassium levels at the start
(median 4 mEq ⁄L) and the end (median
3.94 mEq ⁄L; p 0.87) of the ABLC treatment.
There was no significant correlation between
the final potassium level and the mean daily
dose of ABLC (Spearman correlation coefficient
0.14), or between the final potassium level and
the total accumulated dose of ABLC (Spearman
correlation coefficient 0.23). Haemoglobin values
remained stable, except for a single episode
of anaemia in the last week of treatment, to
which other factors may have contributed. There
was no significant relationship between
the total accumulated dose of ABLC and hae-
moglobin levels (Spearman correlation coeffi-
cient 0.17).
The median maximum concentration of biliru-
bin following treatment was 1.37 ± 7.36 mg ⁄dL
(range 0.30–47 mg ⁄dL). The changes remained
stable over the treatment period. There was no
significant correlation between the maximum
concentration of bilirubin during treatment and
the mean daily dose of ABLC (correlation coeffi-
cient 0.47) or the total accumulated dose of ABLC
(correlation coefficient 0.23). Similarly, the con-
centrations of liver transaminases remained stable
during the study.
Adverse effects registered in the study
In total, 82 adverse effects were recorded during
the study (Table 4). Of these, 75 were categorised
as either slight (n = 27; 36%), moderate (n = 23;
31%) or serious (n = 25; 33%). In 72 cases, the
adverse event was considered to be related
(n = 22; 31%), possibly related (n = 26; 36%) or
unrelated (n = 24; 33%) to the administration of
ABLC.
In the subgroup of 48 patients in whom the
adverse effects were considered to be related or
possibly related to the use of ABLC, the attending
physician opted to suspend (nine patients) or
reduce (three patients) the dose administered, to
continue the administration with additional medi-
cation for alleviation of symptoms in 14 (29%)
patients, and to continue without any corrective
medication, because the reactions were either
slight or moderate and did not require interven-
tion, in the 22 (46%) remaining patients.
DISCUSSION
The main objective of the present study was to
quantify the risk of toxicity associated with the use
of ABLC. Special attention was given to potential
nephrotoxicity, particularly in high-risk patients,
such as those who had previously received other
nephrotoxic drugs, those who had previously
suffered some type of nephrotoxicity, or those
who had an elevated risk of deteriorating renal
function secondary to their underlying illness.
Data were also gathered on the real risk of adverse
events related to the use of ABLC.
Of the patients who received treatment with
ABLC, 58%had either relapsed following previous
treatment with another antifungal preparation, or
had developed toxicity with amphotericin B, or
had pre-existing renal insufficiency. In addition, at
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Fig. 2. Median serum creatinine concentration change
following treatment with amphotericin B lipid complex
for patients with baseline creatinine values ‡ 2 mg ⁄dL.
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least 33% of the study patients had renal deterior-
ation before starting treatment with ABLC. Never-
theless, at the end of the study there were no major
variations in creatinine concentrations within the
overall patient group over the long term (Fig. 1),
including 20 patients in whom the initial creatinine
concentration was > 2 mg ⁄dL. Similarly, there was
no clinically relevant toxicity, and the percentage of
patients with creatinine levels > 2 mg ⁄dL was
similar at the beginning of the study and at the
end of treatment.
There was a non-significant tendency for a
decrease in serum creatinine levels among
patients who received ABLC because of
pre-existing renal insufficiency, either related or
unrelated to previous treatment with conven-
tional amphotericin B. However, because of the
small sample size, it was difficult to reach
unambiguous conclusions regarding the risk of
renal toxicity in patients who received cyclosp-
orin. None of these patients developed renal
toxicity associated with the concomitant use of
ABLC. The absence of a relationship between the
total dose of ABLC and the serum creatinine
levels indicated a low risk of nephrotoxicity
associated with the use of ABLC. No significant
increase was observed in anaemia, hypokalae-
mia, hyper-bilirubinaemia or levels of transam-
inases.
The number of significant adverse events
associated with the use of ABLC was low. The
most frequent adverse reaction was fever with
chills during infusion of the agent. This was
recorded for 23% of the patients in the study,
but in most cases only at the time of the first
dose, and it was controlled effectively with the
use of appropriate pre-medication. A transitory
increase in serum creatinine level was observed
in 19.5% of patients, but this resolved sponta-
neously within a few days without any modifi-
cation of the ABLC treatment guidelines.
Hypokalaemia was observed in 12% of the
patients, but was controlled with external sup-
port, so that it was necessary to suspend ABLC
treatment for only one patient. Most (66%) of
the adverse events reported were considered to
be ‘slight or moderate’, and it was considered
necessary to reduce the dose or to suspend
ABLC treatment for only seven patients. Most
reactions (e.g., slight increase in serum creatinine
concentration, fever ⁄ chills and hypokalaemia)
were controlled easily without suspending the
administration of ABLC.
It was concluded that ABLC is a safe drug for
the treatment of mycoses. It did not induce
appreciable nephrotoxicity, despite being admin-
istered to high-risk patients. The slight increase in
serum creatinine concentration observed in some
patients was reversed in most patients simply by
reducing the dose of ABLC. However, this was a
non-randomised study and did not allow a
definitive appreciation of the renal tolerance of
ABLC. The adverse events occurring during the
infusion of ABLC affected about 20% of these
patients, but in only one case was it necessary to
withdraw the drug.
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